Novogen appoints new Chairman

Company News

Novogen (ASX:NRT) has appointed Mr John O'Connor Chairman and Mr Bryce Carmine Deputy Chairman.

The company has also appointed incoming CEO, Dr James Garner,  to the Board as an Executive Director, meaning former Acting CEO, Mr Iain Ross, will resume his role on the Board as a Non-Executive Director. Dr Garner joined the company as CEO on 1 February.

In a letter to shareholders last week, Dr Garner said he would review the company’s most advanced programs – Cantrixil, Anisina and Trilexiu - with the goal to progress their development “in the fastest and most effective way possible.”

Mr O’Connor has been Deputy Chairman of Novogen since 2014 and takes over from Mr Ian Phillips who was appointed Interim Chairman in July 2015. He is a long-term shareholder in the company and has more than three decades experience in the financial industry, having held numerous management roles as a fund manager and stockbroker.

Mr O’Connor paid tribute to Mr Phillips for his contribution as Interim Chairman over the past seven months.

“Ian took over as Chairman at a time when the Company was undergoing a period of transition and he has been instrumental in leading the Company to the point where we have a clear strategy in place," said Mr O'Connor. "I am pleased Ian has agreed to remain on the Board as he brings invaluable experience and contacts that we can call upon as we build the Company going forward.”

Mr Phillips said he was "very proud" to have led the company through a transition phase.

"We now have a strong Board and Management Team in place. I want to thank Iain, who as Acting CEO, has worked tirelessly behind the scenes with the Management Team and who was instrumental in helping us attract James Garner as our permanent CEO. Both Iain and I intend to remain as active Board members and look forward to playing our part in building Novogen.”